NXSTAGE REPORTS RECORD SECOND QUARTER 2014 FINANCIAL RESULTS AND INCREASES FULL-YEAR REVENUE GUIDANCE
| |
| • | Revenue Increases to $74.1 million, up 13% from Q2'13 |
| |
| • | Home Revenue Increases to $38.5 million, up 18% from Q2'13 |
| |
| • | Company Expects to Top 15% Annual Growth Target for Home in 2014 |
| |
| • | Company Increases Full-Year 2014 Revenue Guidance to be between $290 and $293 million |
LAWRENCE, Mass., August 7, 2014, --NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported second quarter revenue that exceeds the top end of its guidance range.
Revenue for the second quarter of 2014 increased 13 percent to a record $74.1 million, compared with revenue of $65.5 million for the second quarter of 2013, and exceeded the Company's guidance range for the second quarter. The increase in revenue was driven by strong adoption of the NxStage® System OneTM hemodialysis machine within the Home, both within US and international markets, and the Critical Care market.
Home revenue increased 18 percent to $38.5 million for the second quarter of 2014 compared with revenue of $32.7 million for the second quarter of 2013.
Critical Care revenue increased 15 percent to $12.4 million for the second quarter of 2014 compared with revenue of $10.8 million for the second quarter of 2013.
In-center revenue was $21.0 million for the second quarter of 2014 compared with revenue of $21.2 million for the second quarter of 2013.
NxStage reported a net loss of $7.1 million, or $(0.12) per share for the second quarter of 2014 compared with a net loss of $3.4 million, or $(0.06) per share for the second quarter of 2013. Consistent with the Company's expectations, net loss for the second quarter of 2014 included $3.2 million in losses associated with the Company's market development activities with NxStage Kidney Care, which is designed to support the adoption of home hemodialysis.
"We are very pleased with our performance throughout the first half of the year which reflects continuing momentum with our strategic growth initiatives," stated Jeffrey H. Burbank, Founder and Chief Executive Officer of NxStage. "Home is tracking ahead of plan with second quarter revenue up 18%, representing the best year over year growth in Home since Q4 of 2011. Consistent with our plans, we are accelerating adoption of home hemodialysis with the System One and building a long-term sustainable growth path for NxStage. Based on our strong start to the year, as well as our increased confidence in the second half,we believe we are well positioned to top our 15% annual Home revenue growth target and exceed our previous guidance for total revenue."
Guidance:
The Company now expects full-year revenue for 2014 to be between $290 and $293 million, versus its previous guidance of $283 to $288 million. The Company's full-year net loss guidance remains unchanged at $23 to $27 million.
For the third quarter of 2014, the Company expects revenue to be in a range of $71.0 and $72.5 million, and a net loss in the range of $7.5 to $8.5 million.
Conference Call:
NxStage will also host a conference call today, Thursday, August 7, 2014 at 9:00 a.m. Eastern Time to discuss its second quarter financial results. To listen to the conference call, please dial 877-392-9886 (domestic) or 707-287-9329 (international). The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at http://ir.nxstage.com.
A replay of the conference call will be available two hours after the completion of the call through August 15, 2014. To access the replay, dial 855-859-2056 (domestic) or 404-537-3406 (international) and reference conference ID 75983589. An online archive of the conference call can be accessed via the investor relations section of the Company's website at http://ir.nxstage.com.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the FDA. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow™ SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation, and at a medically appropriate treatment frequency. http://www.nxstage.com/.
About NxStage
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for the Company's products, anticipated operating results, including revenues, loss, gross margin, and other expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products domestically and internationally, growth in home and/or more frequent hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and more frequent hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our customers, including DaVita Healthcare Partners Inc. and Fresenius Medical Care, including in response to the Company's NxStage
Kidney Care initiative, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.
In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.
|
|
| Contact: |
| Kristen K. Sheppard, Esq. |
| VP, Investor Relations |
| ksheppard@nxstage.com |
NxStage Medical, Inc.
Condensed Consolidated Statements of Comprehensive Loss
(in thousands, except per share data)
(unaudited)
|
| | | | | | | | | | | | | | | |
| | Three Months Ended June 30, | | Six Months Ended June 30, |
| | 2014 | | 2013 | | 2014 | | 2013 |
| | |
| Revenues | $ | 74,083 |
| | $ | 65,462 |
| | $ | 146,304 |
| | $ | 127,106 |
|
| Cost of revenues | 46,553 |
| | 40,375 |
| | 89,840 |
| | 78,019 |
|
| Gross profit | 27,530 |
| | 25,087 |
| | 56,464 |
| | 49,087 |
|
| Operating expenses: | | | | | | | |
| Selling and marketing | 13,589 |
| | 11,716 |
| | 26,807 |
| | 22,412 |
|
| Research and development | 5,708 |
| | 4,366 |
| | 10,842 |
| | 9,474 |
|
| Distribution | 6,485 |
| | 5,037 |
| | 13,035 |
| | 9,945 |
|
| General and administrative | 8,399 |
| | 8,239 |
| | 17,220 |
| | 16,063 |
|
| Total operating expenses | 34,181 |
| | 29,358 |
| | 67,904 |
| | 57,894 |
|
| Loss from operations | (6,651 | ) | | (4,271 | ) | | (11,440 | ) | | (8,807 | ) |
| Other expense: | | | | | | | |
| Interest expense | (195 | ) | | (150 | ) | | (393 | ) | | (300 | ) |
| Other (expense) income, net | (17 | ) | | (10 | ) | | 6 |
| | (186 | ) |
| | (212 | ) | | (160 | ) | | (387 | ) | | (486 | ) |
| Net loss before income taxes | (6,863 | ) | | (4,431 | ) | | (11,827 | ) | | (9,293 | ) |
| Provision for (benefit from) income taxes | 332 |
| | (1,026 | ) | | 678 |
| | (894 | ) |
| Net loss | (7,195 | ) | | (3,405 | ) | | (12,505 | ) | | (8,399 | ) |
| Less: Net loss attributable to noncontrolling interests | (82 | ) | | — |
| | (117 | ) | | — |
|
| Net loss attributable to stockholders of NxStage Medical, Inc. | $ | (7,113 | ) | | $ | (3,405 | ) | | $ | (12,388 | ) | | (8,399 | ) |
| | | | | | | | |
| Net loss per share, basic and diluted | $ | (0.12 | ) | | $ | (0.06 | ) | | $ | (0.20 | ) | | $ | (0.14 | ) |
| Weighted-average shares outstanding, basic and diluted | 61,469 |
| | 60,036 |
| | 61,484 |
| | 59,706 |
|
| | | | | | | | |
| Other comprehensive income (loss) | 173 |
| | (704 | ) | | 355 |
| | (559 | ) |
| Total comprehensive loss | (7,022 | ) | | (4,109 | ) | | (12,150 | ) | | (8,958 | ) |
| Less: Comprehensive loss attributable to noncontrolling interests | (82 | ) | | — |
| | (117 | ) | | — |
|
| Total comprehensive loss attributable to stockholders of NxStage Medical, Inc. | $ | (6,940 | ) | | $ | (4,109 | ) | | $ | (12,033 | ) | | $ | (8,958 | ) |
NxStage Medical, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share data)
(unaudited)
|
| | | | | | | |
| | June 30, | | December 31, |
| | 2014 | | 2013 |
| | | | |
| ASSETS | | | |
| Current assets: | | | |
| Cash and cash equivalents | $ | 62,079 |
| | $ | 84,134 |
|
| Accounts receivable, net | 31,086 |
| | 20,158 |
|
| Inventory | 43,350 |
| | 37,801 |
|
| Prepaid expenses and other current assets | 4,537 |
| | 4,027 |
|
| Total current assets | 141,052 |
| | 146,120 |
|
| Property and equipment, net | 60,629 |
| | 52,478 |
|
| Field equipment, net | 17,808 |
| | 13,041 |
|
| Deferred cost of revenues | 33,097 |
| | 34,730 |
|
| Intangible assets, net | 15,802 |
| | 17,194 |
|
| Goodwill | 41,817 |
| | 41,817 |
|
| Other assets | 2,573 |
| | 1,582 |
|
| Total assets | $ | 312,778 |
| | $ | 306,962 |
|
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | |
| Current liabilities: | | | |
| Accounts payable | $ | 22,525 |
| | $ | 14,610 |
|
| Accrued expenses | 21,195 |
| | 21,025 |
|
| Current portion of long-term debt | 103 |
| | 102 |
|
| Other current liabilities | 1,870 |
| | 1,870 |
|
| Total current liabilities | 45,693 |
| | 37,607 |
|
| Deferred revenues | 51,831 |
| | 53,277 |
|
| Long-term debt | 1,004 |
| | 1,044 |
|
| Other long-term liabilities | 24,030 |
| | 20,273 |
|
| Total liabilities | 122,558 |
| | 112,201 |
|
| Commitments and contingencies | | | |
| Stockholders’ equity: | | | |
| Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2014 and December 31, 2013 | — |
| | — |
|
| Common stock: par value $0.001, 100,000,000 shares authorized; 62,185,421 and 61,666,048 shares issued as of June 30, 2014 and December 31, 2013, respectively | 62 |
| | 61 |
|
| Additional paid-in capital | 575,123 |
| | 567,468 |
|
| Accumulated deficit | (375,930 | ) | | (363,542 | ) |
| Accumulated other comprehensive income | 567 |
| | 212 |
|
| Treasury stock, at cost: 579,121 and 575,895 shares as of June 30, 2014 and December 31, 2013, respectively | (10,010 | ) | | (9,963 | ) |
| Total NxStage Medical, Inc. stockholders' equity | 189,812 |
| | 194,236 |
|
| Noncontrolling interest | 408 |
| | 525 |
|
| Total stockholders' equity | 190,220 |
| | 194,761 |
|
| Total liabilities and stockholders’ equity | $ | 312,778 |
| | $ | 306,962 |
|
| | | | |
NxStage Medical, Inc.
Cash Flows from Operating Activities
(in thousands)
(unaudited)
|
| | | | | | | |
| | Six Months Ended June 30, |
| | 2014 | | 2013 |
| | | | |
| Cash flows from operating activities: | | | |
| Net loss | $ | (12,505 | ) | | $ | (8,399 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | |
| Depreciation and amortization | 13,343 |
| | 12,259 |
|
| Stock-based compensation | 5,740 |
| | 5,435 |
|
| Other | 450 |
| | 1,226 |
|
| Changes in operating assets and liabilities: | | | |
| Accounts receivable | (10,927 | ) | | (1,853 | ) |
| Inventory | (17,523 | ) | | (12,067 | ) |
| Prepaid expenses and other assets | (550 | ) | | (2,584 | ) |
| Accounts payable | 7,948 |
| | 1,955 |
|
| Accrued expenses and other liabilities | 1,206 |
| | (1,270 | ) |
| Deferred revenues | (1,395 | ) | | (4,439 | ) |
| Net cash used in operating activities | $ | (14,213 | ) | | $ | (9,737 | ) |
NxStage Medical, Inc.
Revenues by Segment
(in thousands)
(unaudited)
|
| | | | | | | | | | | | | | | |
| | Three Months Ended June 30, | | Six Months Ended June 30, |
| | 2014 | | 2013 | | 2014 | | 2013 |
| System One segment | | | | | | | |
| Home | $ | 38,488 |
| | $ | 32,671 |
| | $ | 74,983 |
| | $ | 64,130 |
|
| Critical Care | 12,422 |
| | 10,826 |
| | 27,114 |
| | 21,536 |
|
| Total System One segment | 50,910 |
| | 43,497 |
| | 102,097 |
| | 85,666 |
|
| In-Center segment | 21,003 |
| | 21,238 |
| | 39,919 |
| | 39,938 |
|
| Other | 1,943 |
| | 727 |
| | 3,997 |
| | 1,502 |
|
| Products subtotal | 73,856 |
| | 65,462 |
| | 146,013 |
| | 127,106 |
|
| Services segment | 428 |
| | — |
| | 544 |
| | — |
|
| Elimination of intersegment revenues | (201 | ) | | — |
| | (253 | ) | | — |
|
| Total | $ | 74,083 |
| | $ | 65,462 |
| | $ | 146,304 |
| | $ | 127,106 |
|
